Cancer Immunotherapy
T cells with dual receptors suppress cancer growth
Published in Gene Therapy Weekly, September 16th, 2004
According to recent research from Germany, "grafting T cells with new antigen specificity by T cell receptor (TCR) gene transfer could greatly facilitate adoptive T cell immunotherapy. Little is known about how two TCR on one T cell influence each other. Among other reasons, this is often due to the fact that only one TCR specificity is known."
"We have genetically generated murine dual TCR T cells (OT-I/P14), specific for ovalbumin (ova257) and lymphocyte choriomeningitis virus glycoprotein (gp33). These cells retain both specificities and can be stimulated by either antigenic peptide to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-09-16)
More Articles from Gene Therapy Weekly
- Cardiomyopathy
Partial-heart dystrophin gene transfer may correct hereditary heart disease - Immunology
Retinal transduction does not generate immune tolerance to transgene products - Neuroscience
Dual-cell, dual-gene therapy provides neuroprotection against excitotoxicity - Oncology
Virus-mediated p14(ARF) expression prompts apoptosis in osteosarcoma cells - Pulmonary Medicine
Adenovirus vectors trigger survival signals in the lungs - AIDS/HIV Vaccine
Camelized VH intrabodies against vif neutralize HIV-1 infectivity - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
